Welcome to

ClinMicroNow

Manual of Clinical Microbiology

First page image

ABSTRACT

Wuchereria bancrofti, Brugia malayi, and Brugia timori belong to clade III (Chromadoria: Spirurina) of the Nematoda, in the superfamily Spiruromorpha, and the family Onchocercidae.…

REFERENCES

  • 1. Adl SM, Simpson AG, Lane CE, Lukeš J, Bass D, Bowser SS, Brown MW, Burki F, Dunthorn M, Hampl V, Heiss A, Hoppenrath M, Lara E, Le Gall L, Lynn DH, McManus H, Mitchell EA, Mozley‐Stanridge SE, Parfrey LW, Pawlowski J, Rueckert S, Shadwick L, Schoch CL, Smirnov A, Spiegel FW. 2012. The revised classification of eukaryotes. J Eukaryot Microbiol 59:429–493. Google Scholar
  • 2. Lipner EM, Law MA, Barnett E, Keystone JS, Sonnenburg F, Loutan L, Prevots DR, Klion AD, Nutman TB, Network GeoSentinel Surveillance. 2007. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PLoS Negl Trop Dis 1:e88. Google Scholar
  • 3. Antinori S, Schifanella L, Million M, Galimberti L, Ferraris L, Mandia L, Trabucchi G, Cacioppo V, Monaco G, Tosoni A, Brouqui P, Gismondo MR, Giuliani G, Corbellino M. 2012. Imported Loa loa filariasis: three cases and a review of cases reported in non‐endemic countries in the past 25 years. Int J Infect Dis 16:e649–e662. Google Scholar
  • 4. Mathison BA, Couturier MR, Pritt BS. 2019. Diagnostic identification and differentiation of microfilariae. J Clin Microbiol 57:e00706–e00719. Google Scholar
  • 5. Showler AJ, Kubofcik J, Ricciardi A, Nutman TB. 2019. Differences in the clinical and laboratory features of imported onchocerciasis in endemic individuals and temporary residents. Am J Trop Med Hyg 100:1216–1222. Google Scholar
  • 6. Showler AJ, Nutman TB. 2018. Imported onchocerciasis in migrants and travelers. Curr Opin Infect Dis 31:393–398. Google Scholar
  • 7. Herrick JA, Metenou S, Makiya MA, Taylar‐Williams CA, Law MA, Klion AD, Nutman TB. 2015. Eosinophil‐associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to Loa‐endemic areas. Clin Infect Dis 60:55–63. Google Scholar
  • 8. Araújo PSR, Souza Junior VR, Souza A, Barros Correia Fontes L, Brandao E, Rocha A. 2018. Chiluria in a lymphatic filariasis endemic area. BMC Res Notes 11:269. Google Scholar
  • 9. Vijayan VK. 2007. Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. Curr Opin Pulm Med 13:428–433. Google Scholar
  • 10. Sasa M. 1976. Human Filariasis. A Global Survey of Epidemiology and Control. University Park Press, Baltimore, MD. Google Scholar
  • 11. Freedman DO, Almeida Filho PJ, Besh S, Maia e Silva MC, Braga C, Maciel A. 1994. Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis. J Infect Dis 170:927–933. Google Scholar
  • 12. Norões J, Addiss D, Santos A, Medeiros Z, Coutinho A, Dreyer G. 1996. Ultrasonographic evidence of abnormal lymphatic vessels in young men with adult Wuchereria bancrofti infection in the scrotal area. J Urol 156:409–412. Google Scholar
  • 13. Dreyer G, Norões J, Figueredo‐Silva J, Piessens WF. 2000. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today 16:544–548. Google Scholar
  • 14. Dreyer G, Addiss D, Roberts J, Norões J. 2002. Progression of lymphatic vessel dilatation in the presence of living adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 96:157–161. Google Scholar
  • 15. Pani SP, Srividya A. 1995. Clinical manifestations of bancroftian filariasis with special reference to lymphoedema grading. Indian J Med Res 102:114–118. Google Scholar
  • 16. Olszewski WL, Jamal S, Manokaran G, Pani S, Kumaraswami V, Kubicka U, Lukomska B, Tripathi FM, Swoboda E, Meisel‐Mikolajczyk F, Stelmach E, Zaleska M. 1999. Bacteriological studies of blood, tissue fluid, lymph and lymph nodes in patients with acute dermatolymphangioadenitis (DLA) in course of ‘filarial’ lymphedema. Acta Trop 73:217–224. Google Scholar
  • 17. Shenoy RK, Sandhya K, Suma TK, Kumaraswami V. 1995. A preliminary study of filariasis related acute adenolymphangitis with special reference to precipitating factors and treatment modalities. Southeast Asian J Trop Med Public Health 26:301–305. Google Scholar
  • 18. Ananthakrishnan S, Das LK. 2004. Entry lesions in bancroftian filarial lymphoedema patients—a clinical observation. Acta Trop 90:215–218. Google Scholar
  • 19. Dreyer G, Medeiros Z, Netto MJ, Leal NC, Castro LG, Piessens WF. 1999. Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg 93:413–417. Google Scholar
  • 20. McPherson T, Persaud S, Singh S, Fay MP, Addiss D, Nutman TB, Hay R. 2006. Interdigital lesions and frequency of acute dermatolymphangioadenitis in lymphoedema in a filariasis‐endemic area. Br J Dermatol 154:933–941. Google Scholar
  • 21. Shenoy RK, Kumaraswami V, Suma TK, Rajan K, Radhakuttyamma G. 1999. A double‐blind, placebo‐controlled study of the efficacy of oral penicillin, diethylcarbamazine or local treatment of the affected limb in preventing acute adenolymphangitis in lymphoedema caused by brugian filariasis. Ann Trop Med Parasitol 93:367–377. Google Scholar
  • 22. Pani SP, Yuvaraj J, Vanamail P, Dhanda V, Michael E, Grenfell BT, Bundy DA. 1995. Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis. Trans R Soc Trop Med Hyg 89:72–74. Google Scholar
  • 23. Adesiyun AG, Samaila MO. 2008. Huge filarial elephantiasis vulvae in a Nigerian woman with subfertility. Arch Gynecol Obstet 278:597–600. Google Scholar
  • 24. Palanisamy AP, Kanakaram KK, Vadivel S, Kothandapany S. 2015. Vulval elephantiasis. Indian Dermatol Online J 6:371–371. Google Scholar
  • 25. Ottesen EA, Nutman TB. 1992. Tropical pulmonary eosinophilia. Annu Rev Med 43:417–424. Google Scholar
  • 26. Pinkston P, et al. 1987. Acute tropical pulmonary eosinophilia. Characterization of the lower respiratory tract inflammation and its response to therapy. J Clin Invest 80:216–225. Google Scholar
  • 27. Udwadia FE. 1993. Tropical eosinophilia: a review. Respir Med 87:17–21. Google Scholar
  • 28. Amaral F, Dreyer G, Figueredo‐Silva J, Noroes J, Cavalcanti A, Samico SC, Santos A, Coutinho A. 1994. Live adult worms detected by ultrasonography in human bancroftian filariasis. Am J Trop Med Hyg 50:753–757. Google Scholar
  • 29. Mand S, Supali T, Djuardi J, Kar S, Ravindran B, Hoerauf A. 2006. Detection of adult Brugia malayi filariae by ultrasonography in humans in India and Indonesia. Trop Med Int Health 11:1375–1381. Google Scholar
  • 30. Shenoy RK, Suma TK, Kumaraswami V, Padma S, Rahmah N, Abhilash G, Ramesh C. 2007. Doppler ultrasonography reveals adult‐worm nests in the lymph vessels of children with brugian filariasis. Ann Trop Med Parasitol 101:173–180. Google Scholar
  • 31. Eberhard ML, Lammie PJ. 1991. Laboratory diagnosis of filariasis. Clin Lab Med 11:977–1010. Google Scholar
  • 32. Chesnais CB, Awaca‐Uvon N‐P, Bolay FK, Boussinesq M, Fischer PU, Gankpala L, Meite A, Missamou F, Pion SD, Weil GJ. 2017. A multi‐center field study of two point‐of‐care tests for circulating Wuchereria bancrofti antigenemia in Africa. PLoS Negl Trop Dis 11:e0005703. Google Scholar
  • 33. Tisch DJ, Bockarie MJ, Dimber Z, Kiniboro B, Tarongka N, Hazlett FE, Kastens W, Alpers MP, Kazura JW. 2008. Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation. Am J Trop Med Hyg 78:289–293. Google Scholar
  • 34. Wanji S, Amvongo‐Adjia N, Koudou B, Njouendou AJ, Chounna Ndongmo PW, Kengne‐Ouafo JA, Datchoua‐Poutcheu FR, Fovennso BA, Tayong DB, Fombad FF, Fischer PU, Enyong PI, Bockarie M. 2015. Cross‐reactivity of filariais ICT cards in areas of contrasting endemicity of Loa loa and Mansonella perstans in Cameroon: implications for shrinking of the lymphatic filariasis map in the Central African region. PLoS Negl Trop Dis 9:e0004184. Google Scholar
  • 35. Pion SD, Montavon C, Chesnais CB, Kamgno J, Wanji S, Klion AD, Nutman TB, Boussinesq M. 2016. Positivity of antigen tests used for diagnosis of lymphatic filariasis in individuals without Wuchereria bancrofti infection but with high Loa loa microfilaremia. Am J Trop Med Hyg 95:1417–1423. Google Scholar
  • 36. Rahumatullah A, Lim TS, Yunus MH, Noordin R. 2019. Development of an antigen detection ELISA for bancroftian filariasis using BmSXP‐specific recombinant monoclonal antibody. Am J Trop Med Hyg 101:436–440. Google Scholar
  • 37. Fink DL, Fahle GA, Fischer S, Fedorko DF, Nutman TB. 2011. Toward molecular parasitologic diagnosis: enhanced diagnostic sensitivity for filarial infections in mobile populations. J Clin Microbiol 49:42–47. Google Scholar
  • 38. McCarthy JS, Zhong M, Gopinath R, Ottesen EA, Williams SA, Nutman TB. 1996. Evaluation of a polymerase chain reaction‐based assay for diagnosis of Wuchereria bancrofti infection. J Infect Dis 173:1510–1514. Google Scholar
  • 39. Zhong M, McCarthy J, Bierwert L, Lizotte‐Waniewski M, Chanteau S, Nutman TB, Ottesen EA, Williams SA. 1996. A polymerase chain reaction assay for detection of the parasite Wuchereria bancrofti in human blood samples. Am J Trop Med Hyg 54:357–363. Google Scholar
  • 40. Rao RU, Huang Y, Bockarie MJ, Susapu M, Laney SJ, Weil GJ. 2009. A qPCR‐based multiplex assay for the detection of Wuchereria bancrofti, Plasmodium falciparum and Plasmodium vivax DNA. Trans R Soc Trop Med Hyg 103:365–370. Google Scholar
  • 41. Rao RU, Weil GJ, Fischer K, Supali T, Fischer P. 2006. Detection of Brugia parasite DNA in human blood by real‐time PCR. J Clin Microbiol 44:3887–3893. Google Scholar
  • 42. Pilotte N, Torres M, Tomaino FR, Laney SJ, Williams SA. 2013. A TaqMan‐based multiplex real‐time PCR assay for the simultaneous detection of Wuchereria bancrofti and Brugia malayi. Mol Biochem Parasitol 189:33–37. Google Scholar
  • 43. Kubofcik J, Fink DL, Nutman TB. 2012. Identification of Wb123 as an early and specific marker of Wuchereria bancrofti infection. PLoS Negl Trop Dis 6:e1930. Google Scholar
  • 44. Steel C, Golden A, Kubofcik J, LaRue N, Los Santos T, Domingo GJ, Nutman TB. 2013. Rapid Wuchereria bancrofti‐specific antigen Wb123‐based IgG4 immunoassays as tools for surveillance following mass drug administration programs on lymphatic filariasis. Clin Vaccine Immunol 20:1155–1161. Google Scholar
  • 45. Steel C, Golden A, Stevens E, Yokobe L, Domingo GJ, Santos T, Nutman TB. 2015. Rapid point‐of‐contact tool for mapping and integrated surveillance of Wuchereria bancrofti and Onchocerca volvulus infection. Clin Vaccine Immunol 22:896–901. Google Scholar
  • 46. Noordin R, Yunus MH, Robinson K, Won KY, Babu S, Fischer PU, Hisam S, Mahmud R. 2018. Laboratory evaluation of a rapid IgG4 antibody test (BLF Rapid™) for bancroftian filariasis. Am J Trop Med Hyg 99:1587–1590. Google Scholar
  • 47. Noordin R, Shenoy RK, Rahman RA. 2003. Comparison of two IgG4 assay formats (ELISA and rapid dipstick test) for detection of brugian filariasis. Southeast Asian J Trop Med Public Health 34:768–770. Google Scholar
  • 48. Rahmah N, Shenoy RK, Nutman TB, Weiss N, Gilmour K, Maizels RM, Yazdanbakhsh M, Sartono E. 2003. Multicentre laboratory evaluation of Brugia Rapid dipstick test for detection of brugian filariasis. Trop Med Int Health 8:895–900. Google Scholar
  • 49. Ouattara AF, Bjerum CM, Aboulaye M, Kouadio O, Marius VK, Andersen B, Lew D, Goss CW, Weil GJ, Koudou BG, King CL. 2021. Semiannual treatment of albendazole alone is efficacious for treatment of lymphatic filariasis: a randomized open‐label trial in Cote d'Ivoire. Clin Infect Dis ciab194. Google Scholar
  • 50. Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, Ottesen EA. 2014. Global programme to eliminate lymphatic filariasis: the processes underlying programme success. PLoS Negl Trop Dis 8:e3328. Google Scholar
  • 51. Fox LM, Furness BW, Haser JK, Desire D, Brissau JM, Milord MD, Lafontant J, Lammie PJ, Beach MJ. 2005. Tolerance and efficacy of combined diethylcarbamazine and albendazole for treatment of Wuchereria bancrofti and intestinal helminth infections in Haitian children. Am J Trop Med Hyg 73:115–121. Google Scholar
  • 52. Tisch DJ, Michael E, Kazura JW. 2005. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis 5:514–523. Google Scholar
  • 53. Dreyer G, Addiss D, Williamson J, Norões J. 2006. Efficacy of co‐administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 100:1118–1125. Google Scholar
  • 54. Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, Schmidt MS, Siba PM, Weil GJ, Kazura JW, Fleckenstein LL, King CL. 2016. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis 62:334–341. Google Scholar
  • 55. Bjerum CM, Ouattara AF, Aboulaye M, Kouadio O, Marius VK, Andersen BJ, Weil GJ, Koudou BG, King CL. 2020. Efficacy and safety of a single dose of ivermectin, diethylcarbamazine, and albendazole for treatment of lymphatic filariasis in Côte d'Ivoire: an open‐label randomized controlled trial. Clin Infect Dis 71:e68–e75. Google Scholar
  • 56. Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, Rahi M, Somani RK, Suryaprakash MK, Dwivedi GP, Weil GJ. 2021. An open label, block randomized, community study of the safety and efficacy of co‐administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLoS Negl Trop Dis 15:e0009069. Google Scholar
  • 57. Dubray CL, Sircar AD, Beau de Rochars VM, Bogus J, Direny AN, Ernest JR, Fayette CR, Goss CW, Hast M, O'Brian K, Pavilus GE, Sabin DF, Wiegand RE, Weil GJ, Lemoine JF. 2020. Safety and efficacy of co‐administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: results from a two‐armed, open‐label, cluster‐randomized, community study. PLoS Negl Trop Dis 14:e0008298. Google Scholar
  • 58. Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, Goss CW, Hardy M, Jambulingam P, King CL, Kuttiat VS, Krishnamoorthy K, Laman M, Lemoine JF, O'Brian KK, Robinson LJ, Samuela J, Schechtman KB, Sircar A, Srividya A, Steer AC, Supali T, Subramanian S, DOLF IDA Safety Study Group. 2019. The safety of double‐ and triple‐drug community mass drug administration for lymphatic filariasis: a multicenter, open‐label, cluster‐randomized study. PLoS Med 16:e1002839. Google Scholar
  • 59. King CL, Suamani J, Sanuku N, Cheng YC, Satofan S, Mancuso B, Goss CW, Robinson LJ, Siba PM, Weil GJ, Kazura JW. 2018. A trial of a triple‐drug treatment for lymphatic filariasis. N Engl J Med 379:1801–1810. Google Scholar
  • 60. Supali T, Djuardi Y, Christian M, Iskandar E, Alfian R, Maylasari R, Destani Y, Lomiga A, Minggu D, Lew D, Bogus J, Weil GJ, Fischer PU. 2021. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia. PLoS Negl Trop Dis 15:e0009294. Google Scholar
  • 61. Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Méité A, Koudou BG, Weil GJ, King CL, Murry DJ. 2019. Pharmacokinetics, safety, and efficacy of a single co‐administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. PLoS Negl Trop Dis 13:e0007325. Google Scholar
  • 62. Hardy M, Samuela J, Kama M, Tuicakau M, Romani L, Whitfeld MJ, King CL, Weil GJ, Grobler AC, Robinson LJ, Kaldor JM, Steer AC. 2021. Individual efficacy and community impact of ivermectin, diethylcarbamazine, and albendazole mass drug administration for lymphatic filariasis control in Fiji: a cluster randomized trial. Clin Infect Dis 73:994–1002. Google Scholar
  • 63. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A. 2005. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double‐blind, randomised placebo‐controlled trial. Lancet 365:2116–2121. Google Scholar
  • 64. Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez M‐G. 2015. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clin Infect Dis 60:1199–1207. Google Scholar
  • 65. Johnston KL, Hong WD, Turner JD, O'Neill PM, Ward SA, Taylor MJ. 2021. Anti‐Wolbachia drugs for filariasis. Trends Parasitol 37:1068–1081. Google Scholar
  • 66. Mand S, Debrah AY, Klarmann U, Batsa L, Marfo‐Debrekyei Y, Kwarteng A, Specht S, Belda‐Domene A, Fimmers R, Taylor M, Adjei O, Hoerauf A. 2012. Doxycycline improves filarial lymphedema independent of active filarial infection: a randomized controlled trial. Clin Infect Dis 55:621–630. Google Scholar
  • 67. Horton J, Klarmann‐Schulz U, Stephens M, Budge PJ, Coulibaly Y, Debrah A, Debrah LB, Krishnasastry S, Mwingira U, Ngenya A, Wanji S, Weerasooriya M, Yahathugoda C, Kroidl I, Deathe D, Majewski A, Sullivan S, Mackenzie C, Nutman TB, Shott JP, Weil G, Ottesen E, Hoerauf A. 2020. The design and development of a multicentric protocol to investigate the impact of adjunctive doxycycline on the management of peripheral lymphoedema caused by lymphatic filariasis and podoconiosis. Parasit Vectors 13:155. Google Scholar
  • 68. World Health Organization. 1992. Lymphatic filariasis: the disease and its control. Fifth report of the WHO Expert Committee on Filariasis. World Health Organ Tech Rep Ser 821:1–71. Google Scholar
  • 69. Capuano GP, Capuano C. 2012. Surgical management of morbidity due to lymphatic filariasis: the usefulness of a standardized international clinical classification of hydroceles. Trop Biomed 29:24–38. Google Scholar
  • 70. Lim KH, Speare R, Thomas G, Graves P. 2015. Surgical treatment of genital manifestations of lymphatic filariasis: a systematic review. World J Surg 39:2885–2899. Google Scholar
  • 71. Local Burden of Disease 2019 Neglected Tropical Diseases Collaborators. 2020. The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis. Lancet Glob Health 8:e1186–e1194. Google Scholar
  • 72. Ottesen EA, Hooper PJ, Bradley M, Biswas G. 2008. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2:e317. Google Scholar
  • 73. Ramaiah KD, Ottesen EA. 2014. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis 8:e3319. Google Scholar
  • 74. Seim AR, Dreyer G, Addiss DG. 1999. Controlling morbidity and interrupting transmission: twin pillars of lymphatic filariasis elimination. Rev Soc Bras Med Trop 32:325–328. Google Scholar
  • 75. Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, Ogbuagu KF, Okello D, Ozoh G, Remme J. 2002. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 96:283–296. Google Scholar
  • 76. Murdoch ME, Hay RJ, Mackenzie CD, Williams JF, Ghalib HW, Cousens S, Abiose A, Jones BR. 1993. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 129:260–269. Google Scholar
  • 77. Murdoch ME, Murdoch IE, Evans J, Yahaya H, Njepuome N, Cousens S, Jones BR, Abiose A. 2017. Pre‐control relationship of onchocercal skin disease with onchocercal infection in Guinea Savanna, Northern Nigeria. PLoS Negl Trop Dis 11:e0005489. Google Scholar
  • 78. Abdul‐Ghani R, Mahdy MAK, Beier JC. 2016. Onchocerciasis in Yemen: time to take action against a neglected tropical parasitic disease. Acta Trop 162:133–141. Google Scholar
  • 79. Puente S, Ramirez‐Olivencia G, Lago M, Subirats M, Perez‐Blazquez E, Bru F, Garate T, Vicente B, Belhassen‐Garcia M, Muro A. 2018. Dermatological manifestations in onchocerciasis: a retrospective study of 400 imported cases. Enferm Infecc Microbiol Clin Engl Ed 36:633–639. Google Scholar
  • 80. Albiez EJ. 1983. Studies on nodules and adult Onchocerca volvulus during a nodulectomy trial in hyperendemic villages in Liberia and Upper Volta. I. Palpable and impalpable onchocercomata. Tropenmed Parasitol 34:54–60. Google Scholar
  • 81. Meyers WM, Neafie RC, Connor DH. 1977. Onchocerciasis: invasion of deep organs by Onchocerca volvulus. Am J Trop Med Hyg 26:650–657. Google Scholar
  • 82. Taylor HR. 1990. Onchocerciasis. Int Ophthalmol 14:189–194. Google Scholar
  • 83. Duke BO. 1998. Onchocerciasis, epilepsy and hyposexual dwarfism. Trans R Soc Trop Med Hyg 92:236. Google Scholar
  • 84. Föger K, Gora‐Stahlberg G, Sejvar J, Ovuga E, Jilek‐Aall L, Schmutzhard E, Kaiser C, Winkler AS. 2017. Nakalanga syndrome: clinical characteristics, potential causes, and its relationship with recently described nodding syndrome. PLoS Negl Trop Dis 11:e0005201. Google Scholar
  • 85. Kaiser C, Pion SD, Boussinesq M. 2013. Case‐control studies on the relationship between onchocerciasis and epilepsy: systematic review and meta‐analysis. PLoS Negl Trop Dis 7:e2147. Google Scholar
  • 86. Pion SDS, Boussinesq M. 2012. Significant association between epilepsy and presence of onchocercal nodules: case‐control study in Cameroon. Am J Trop Med Hyg 86:557. Google Scholar
  • 87. Johnson TP, Sejvar J, Nutman TB, Nath A. 2020. The pathogenesis of nodding syndrome. Annu Rev Pathol 15:395–417. Google Scholar
  • 88. Antinori S, Parravicini C, Galimberti L, Tosoni A, Giunta P, Galli M, Corbellino M, Ridolfo AL. 2017. Is imported onchocerciasis a truly rare entity? Case report and review of the literature. Travel Med Infect Dis 16:11–17. Google Scholar
  • 89. Zimmerman PA, Guderian RH, Aruajo E, Elson L, Phadke P, Kubofcik J, Nutman TB. 1994. Polymerase chain reaction‐based diagnosis of Onchocerca volvulus infection: improved detection of patients with onchocerciasis. J Infect Dis 169:686–689. Google Scholar
  • 90. Golden A, Steel C, Yokobe L, Jackson E, Barney R, Kubofcik J, Peck R, Unnasch TR, Nutman TB, Santos T, Domingo GJ. 2013. Extended result reading window in lateral flow tests detecting exposure to Onchocerca volvulus: a new technology to improve epidemiological surveillance tools. PLoS One 8:e69231. Google Scholar
  • 91. Lipner EM, Dembele N, Souleymane S, Alley WS, Prevots DR, Toe L, Boatin B, Weil GJ, Nutman TB. 2006. Field applicability of a rapid‐format anti‐Ov‐16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity. J Infect Dis 194:216–221. Google Scholar
  • 92. Weil GJ, Steel C, Liftis F, Li BW, Mearns G, Lobos E, Nutman TB. 2000. A rapid‐format antibody card test for diagnosis of onchocerciasis. J Infect Dis 182:1796–1799. Google Scholar
  • 93. Dieye Y, Storey HL, Barrett KL, Gerth‐Guyette E, Di Giorgio L, Golden A, Faulx D, Kalnoky M, Ndiaye MKN, Sy N, Mané M, Faye B, Sarr M, Dioukhane EM, Peck RB, Guinot P, Los Santos T. 2017. Feasibility of utilizing the SD BIOLINE Onchocerciasis IgG4 rapid test in onchocerciasis surveillance in Senegal. PLoS Negl Trop Dis 11:e0005884. Google Scholar
  • 94. Bennuru S, Oduro‐Boateng G, Osigwe C, Del Valle P, Golden A, Ogawa GM, Cama V, Lustigman S, Nutman TB. 2020. Integrating multiple biomarkers to increase sensitivity for the detection of Onchocerca volvulus infection. J Infect Dis 221:1805–1815. Google Scholar
  • 95. Henry NL, Law M, Nutman TB, Klion AD. 2001. Onchocerciasis in a nonendemic population: clinical and immunologic assessment before treatment and at the time of presumed cure. J Infect Dis 183:512–516. Google Scholar
  • 96. Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, Menéndez C, Bardají A, Chaccour C. 2020. Safety of oral ivermectin during pregnancy: a systematic review and meta‐analysis. Lancet Glob Health 8:e92–e100. Google Scholar
  • 97. Boatin BA, Richards FO 2006. Control of onchocerciasis. Adv Parasitol 61:349–394. Google Scholar
  • 98. Gardon J, Gardon‐Wendel N, Demanga‐Ngangue Kamgno J, Chippaux JP, Boussinesq M. 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350:18–22. Google Scholar
  • 99. D'Ambrosio MV, Bakalar M, Bennuru S, Reber C, Skandarajah A, Nilsson L, Switz N, Kamgno J, Pion S, Boussinesq M, Nutman TB, Fletcher DA. 2015. Point‐of‐care quantification of blood‐borne filarial parasites with a mobile phone microscope. Sci Transl Med 7:286re4. Google Scholar
  • 100. Kamgno J, Pion SD, Chesnais CB, Bakalar MH, D'Ambrosio MV, Mackenzie CD, Nana‐Djeunga HC, Gounoue‐Kamkumo R, Njitchouang G‐R, Nwane P, Tchatchueng‐Mbouga JB, Wanji S, Stolk WA, Fletcher DA, Klion AD, Nutman TB, Boussinesq M. 2017. A test‐and‐not‐treat strategy for onchocerciasis in Loa loa‐endemic areas. N Engl J Med 377:2044–2052. Google Scholar
  • 101. Blok DJ, Kamgno J, Pion SD, Nana‐Djeunga HC, Niamsi‐Emalio Y, Chesnais CB, Mackenzie CD, Klion AD, Fletcher DA, Nutman TB, Vlas SJ, Boussinesq M, Stolk WA. 2021. Feasibility of onchocerciasis elimination using a “test‐and‐not‐treat” strategy in Loa loa co‐endemic areas. Clin Infect Dis 72:e1047–e1055. Google Scholar
  • 102. Pion SD, Nana‐Djeunga H, Niamsi‐Emalio Y, Chesnais CB, Deléglise H, Mackenzie C, Stolk W, Fletcher DA, Klion AD, Nutman TB, Boussinesq M, Kamgno J. 2020. Implications for annual retesting after a test‐and‐not‐treat strategy for onchocerciasis elimination in areas co‐endemic with Loa loa infection: an observational cohort study. Lancet Infect Dis 20:102–109. Google Scholar
  • 103. Debrah AY, Specht S, Klarmann‐Schulz U, Batsa L, Mand S, Marfo‐Debrekyei Y, Fimmers R, Dubben B, Kwarteng A, Osei‐Atweneboana M, Boakye D, Ricchiuto A, Büttner M, Adjei O, Mackenzie CD, Hoerauf A. 2015. Doxycycline leads to sterility and enhanced killing of female Onchocerca volvulus worms in an area with persistent microfilaridermia after repeated ivermectin treatment: a randomized, placebo‐controlled, double‐blind trial. Clin Infect Dis 61:517–526. Google Scholar
  • 104. Hoerauf A, Mand S, Adjei O, Fleischer B, Büttner DW. 2001. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 357:1415–1416. Google Scholar
  • 105. Wanji S, Nji TM, Hamill L, Dean L, Ozano K, Njouendou AJ, Abong RA, Obie ED, Amuam A, Ekanya R, Ndongmo WPC, Ndzeshang BL, Fung EG, Nnamdi DB, Nkimbeng DA, Teghen S, Kah E, Piotrowski H, Forrer A, Khan JAM, Woode ME, Niessen L, Watson V, Njoumemi Z, Murdoch ME, Thomson R, Theobald S, Enyong P, Turner JD, Taylor MJ. 2019. Implementation of test‐and‐treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co‐endemicity: the COUNTDOWN consortium multi‐disciplinary study protocol. Parasit Vectors 12:574. Google Scholar
  • 106. Klarmann‐Schulz U, Specht S, Debrah AY, Batsa L, Ayisi‐Boateng NK, Osei‐Mensah J, Mubarik Y, Konadu P, Ricchiuto A, Fimmers R, Arriens S, Dubben B, Ford L, Taylor M, Hoerauf A. 2017. Comparison of doxycycline, minocycline, doxycycline plus albendazole and albendazole alone in their efficacy against onchocerciasis in a randomized, open‐label, pilot trial. PLoS Negl Trop Dis 11:e0005156. Google Scholar
  • 107. Evans DS, Unnasch TR, Richards FO. 2015. Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time. Lancet 385:2151–2152. Google Scholar
  • 108. Molyneux DH. 2009. Filaria control and elimination: diagnostic, monitoring and surveillance needs. Trans R Soc Trop Med Hyg 103:338–341. Google Scholar
  • 109. Zouré HG, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JH. 2011. The geographic distribution of Loa loa in Africa: results of large‐scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 5:e1210. Google Scholar
  • 110. Herrick JA, Legrand F, Gounoue R, Nchinda G, Montavon C, Bopda J, Tchana SM, Ondigui BE, Nguluwe K, Fay MP, Makiya M, Metenou S, Nutman TB, Kamgno J, Klion AD. 2017. Posttreatment reactions after single‐dose diethylcarbamazine or ivermectin in subjects with Loa loa infection. Clin Infect Dis 64:1017–1025. Google Scholar
  • 111. Fink DL, Kamgno J, Nutman TB. 2011. Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia. PLoS Negl Trop Dis 5:e1299. Google Scholar
  • 112. Klion AD, Vijaykumar A, Oei T, Martin B, Nutman TB. 2003. Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll‐SXP‐1, are highly specific for Loa loa infection. J Infect Dis 187:128–133. Google Scholar
  • 113. Pedram B, Pasquetto V, Drame PM, Ji Y, Gonzalez‐Moa MJ, Baldwin RK, Nutman TB, Biamonte MA. 2017. A novel rapid test for detecting antibody responses to Loa loa infections. PLoS Negl Trop Dis 11:e0005741. Google Scholar
  • 114. Gobbi F, Buonfrate D, Boussinesq M, Chesnais CB, Pion SD, Silva R, Moro L, Rodari P, Tamarozzi F, Biamonte M, Bisoffi Z. 2020. Performance of two serodiagnostic tests for loiasis in a non‐endemic area. PLoS Negl Trop Dis 14:e0008187. Google Scholar
  • 115. Klion AD, Ottesen EA, Nutman TB. 1994. Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long‐term follow‐up. J Infect Dis 169:604–610. Google Scholar
  • 116. Herrick JA, Makiya MA, Holland‐Thomas N, Klion AD, Nutman TB. 2021. Infection‐associated immune perturbations resolve 1 year following treatment for Loa loa. Clin Infect Dis 72:789–796. Google Scholar
  • 117. Gobbi F, Bottieau E, Bouchaud O, Buonfrate D, Salvador F, Rojo‐Marcos G, Rodari P, Clerinx J, Treviño B, Herrera‐Ávila JP, Neumayr A, Calleri G, Angheben A, Rothe C, Zammarchi L, Guerriero M, Bisoffi Z. 2018. Comparison of different drug regimens for the treatment of loiasis: a TropNet retrospective study. PLoS Negl Trop Dis 12:e0006917–e0006917. Google Scholar
  • 118. Boussinesq M, Gardon J, Gardon‐Wendel N, Chippaux JP. 2003. Clinical picture, epidemiology and outcome of Loa‐associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2(Suppl 1):S4. Google Scholar
  • 119. Duke BO. 2003. Overview: report of a scientific working group on serious adverse events following mectizan(R) treatment of onchocerciasis in Loa loa endemic areas. Filaria J 2(Suppl 1):S1. Google Scholar
  • 120. Klion AD, Massougbodji A, Horton J, Ekoué S, Lanmasso T, Ahouissou NL, Nutman TB. 1993. Albendazole in human loiasis: results of a double‐blind, placebo‐controlled trial. J Infect Dis 168:202–206. Google Scholar
  • 121. Gobbi F, Buonfrate D, Tamarozzi F, Degani M, Angheben A, Bisoffi Z. 2019. Efficacy of high‐dose albendazole with ivermectin for treating imported loiasis, Italy. Emerg Infect Dis 25:1574–1576. Google Scholar
  • 122. Pion SD, Tchatchueng‐Mbougua JB, Chesnais CB, Kamgno J, Gardon J, Chippaux J‐P, Ranque S, Ernould J‐C, Garcia A, Boussinesq M. 2019. Effect of a single standard dose (150‐200 μg/kg) of ivermectin on Loa loa microfilaremia: systematic review and meta‐analysis. Open Forum Infect Dis 6:ofz019–ofz019. Google Scholar
  • 123. Nutman TB, Miller KD, Mulligan M, Reinhardt GN, Currie BJ, Steel C, Ottesen EA. 1988. Diethylcarbamazine prophylaxis for human loiasis. Results of a double‐blind study. N Engl J Med 319:752–756. Google Scholar
  • 124. Adolph PE, Kagan IG, McQuay RM. 1962. Diagnosis and treatment of Acanthocheilonema perstans filariasis. Am J Trop Med Hyg 11:76–88. Google Scholar
  • 125. Puente S, Lago M, Subirats M, Sanz‐Esteban I, Arsuaga M, Vicente B, Alonso‐Sardon M, Belhassen‐Garcia M, Muro A. 2020. Imported Mansonell perstans infection in Spain. Infect Dis Poverty 9:105. Google Scholar
  • 126. Meyers WM, Connor DH, Harman LE, Fleshman K, Moris R, Neafie RC. 1972. Human streptocerciasis. A clinico‐pathologic study of 40 Africans (Zairians) including identification of the adult filaria. Am J Trop Med Hyg 21:528–545. Google Scholar
  • 127. McNeeley DF, Raccurt CP, Boncy J, Lowrie RC 1989. Clinical evaluation of Mansonella ozzardi in Haiti. Trop Med Parasitol 40:107–110. Google Scholar
  • 128. Lima NF, Veggiani Aybar CA, Dantur Juri MJ, Ferreira MU. 2016. Mansonella ozzardi: a neglected New World filarial nematode. Pathog Glob Health 110:97–107. Google Scholar
  • 129. Vianna LM, Martins M, Cohen MJ, Cohen JM, Belfort R 2012. Mansonella ozzardi corneal lesions in the Amazon: a cross‐sectional study. BMJ Open 2:e001266. Google Scholar
  • 130. Tang TH, López‐Vélez R, Lanza M, Shelley AJ, Rubio JM, Luz SL. 2010. Nested PCR to detect and distinguish the sympatric filarial species Onchocerca volvulus, Mansonella ozzardi and Mansonella perstans in the Amazon Region. Mem Inst Oswaldo Cruz 105:823–828. Google Scholar
  • 131. Almeida Basano S, de Souza Almeida Aranha Camargo J, Fontes G, Pereira AR, Medeiros JF, Oliveira Laudisse MC, Godoi Mattos Ferreira R, LMA Camargo. 2018. Phase III clinical trial to evaluate ivermectin in the reduction of Mansonella ozzardi infection in the Brazilian Amazon. Am J Trop Med Hyg 98:786–790. Google Scholar
  • 132. Calvopina M, Chiluisa‐Guacho C, Toapanta A, Fonseca D, Villacres I. 2019. High prevalence of Mansonella ozzardi infection in the Amazon Region, Ecuador. Emerg Infect Dis 25:2081–2083. Google Scholar
  • 133. Medeiros JF, Fontes G, Nascimento VLD, Rodrigues M, Cohen J, Andrade EV, Pessoa FAC, Martins M. 2018. Sensitivity of diagnostic methods for Mansonella ozzardi microfilariae detection in the Brazilian Amazon Region. Mem Inst Oswaldo Cruz 113:173–177. Google Scholar
  • 134. Tavares da Silva LB, Crainey JL, Ribeiro da Silva TR, Suwa UF, Vicente AC, Fernandes de Medeiros J, Pessoa FA, Luz SL. 2017. Molecular verification of New World Mansonella perstans parasitemias. Emerg Infect Dis 23:545–547. Google Scholar
  • 135. Keiser PB, Coulibaly Y, Kubofcik J, Diallo AA, Klion AD, Traoré SF, Nutman TB. 2008. Molecular identification of Wolbachia from the filarial nematode Mansonella perstans. Mol Biochem Parasitol 160:123–128. Google Scholar
  • 136. Coulibaly YI, Dembele B, Diallo AA, Lipner EM, Doumbia SS, Coulibaly SY, Konate S, Diallo DA, Yalcouye D, Kubofcik J, Doumbo OK, Traore AK, Keita AD, Fay MP, Traore SF, Nutman TB, Klion AD. 2009. A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med 361:1448–1458. Google Scholar
  • 137. Batsa Debrah L, Phillips RO, Pfarr K, Klarmann‐Schulz U, Opoku VS, Nausch N, Owusu W, Mubarik Y, Sander AL, Lämmer C, Ritter M, Layland LE, Jacobsen M, Debrah AY, Hoerauf A. 2019. The efficacy of doxycycline treatment on Mansonella perstans infection: an open‐label, randomized trial in Ghana. Am J Trop Med Hyg 101:84–92. Google Scholar
  • 138. Fischer P, Tukesiga E, Büttner DW. 1999. Long‐term suppression of Mansonella streptocerca microfilariae after treatment with ivermectin. J Infect Dis 180:1403–1405. Google Scholar
  • 139. Gonzalez AA, Chadee DD, Rawlins SC. 1999. Ivermectin treatment of mansonellosis in Trinidad. West Indian Med J 48:231–234. Google Scholar
  • 140. Nutman TB, Nash TE, Ottesen EA. 1987. Ivermectin in the successful treatment of a patient with Mansonella ozzardi infection. J Infect Dis 156:662–665. Google Scholar
  • 141. Krolewiecki AJ, Cajal SP, Villalpando C, Gil JF. 2011. Ivermectin‐related adverse clinical events in patients treated for Mansonella ozzardi infections. Rev Argent Microbiol 43:48–50. Google Scholar